696 Background: Patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC) experience significantly worse outcomes when nutritional support is inadequate; characterized by weight loss, GI symptoms, and metabolic derangements. These correlate with increased toxicity, reduced survival, and diminished quality of life. Prior prospective cohorts 1 highlight that most pts deteriorate nutritionally from baseline with a significant reduction in weight (p 36g/L. ESAS completion rate was low (50%). Conclusions: In these early NUANCE results, we observe no significant deterioration in weight, ECOG PS and in maintaining albumin, a marked improvement over the previous cohort suggesting this program helps maintain pt’s nutrition and wellbeing during the critical first 4 months on chemotherapy. This supports the integration of nutritional screening and interprofessional support as a critical component of PDAC routine care to mitigate chemotherapy toxicity and improve patient-centered outcomes. Next steps include building the NUANCE design into a smart-app, providing more accessible support to pts with advanced PDAC. Ref: 1. Knox et al. COMPASS unpublished data. Characteristic/Symptom (ESAS score) N=100(baseline) Baseline value med (range) n(4 mons) 4 mos med (range) P value Weight (Kg) 100 67.0(37.0 – 105.9) 47 63.2(40.6 – 109.2) 0.33 Pain scores 52 3 (0 – 8) 45 1.0 (0 – 8) 0.18 Energy 51 5 (1 – 10) 46 5 (0 – 9) 0.95 Appetite 51 5 (0 – 10) 45 4 (0 – 9) 0.27 Diarrhea 50 1 (0 – 8) 43 0 (0 – 7) 0.67 Baseline n 4 mos n ECOG PS 0/1/2/3 100 13 / 73 / 12 / 2 39 4 / 31 / 3 / 1 0.95
McLaughlin et al. (Sat,) studied this question.